<div id="readability-page-1"><p>Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have earned an average rating of &#34;Moderate Buy&#34; from the eight research firms that are  covering the stock, MarketBeat reports. One analyst  has rated the stock with a sell recommendation, one  has issued  a hold recommendation, five have assigned  a buy recommendation and one  has given a strong buy recommendation to  the company. The average 1 year price target among brokerages that have covered the stock in the last year is $7.20.</p><div><p><span></span><span>Get <strong>Esperion Therapeutics</strong> alerts:</span></p></div><p>A number of research analysts recently commented on ESPR shares. Citigroup  reissued a &#34;market outperform&#34; rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Cantor Fitzgerald  reaffirmed an &#34;overweight&#34; rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Wall Street Zen cut Esperion Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 1st. HC Wainwright  restated a &#34;buy&#34; rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Friday, September 19th. Finally, Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Esperion Therapeutics in a report on Wednesday, October 8th.</p><p><b>Get Our Latest Stock Analysis on Esperion Therapeutics</b></p><h2>Esperion Therapeutics Trading Up 2.3%</h2><p>Shares of ESPR opened at $4.04 on Friday. Esperion Therapeutics has a twelve month low of $0.69 and a twelve month high of $4.13. The firm has a market capitalization of $965.80 million, a P/E ratio of -8.08 and a beta of 1.01. The firm's 50-day moving average is $3.34 and its two-hundred day moving average is $2.42. </p><p>Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.07). The business had revenue of $87.31 million for the quarter, compared to the consensus estimate of $78.33 million.  Analysts predict that  Esperion Therapeutics will post -0.29 EPS for the current year. </p><h2>Insider Activity</h2><p>In other news, CFO Benjamin Halladay sold 7,337 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total transaction of $26,926.79. Following the transaction, the chief financial officer owned 467,525 shares of the company's stock, valued at approximately $1,715,816.75. This trade represents a 1.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own  1.70% of the company's stock. </p><h2>Institutional Trading of Esperion Therapeutics</h2><p>Institutional investors and hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its holdings in  Esperion Therapeutics by 7.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 72,705 shares of the biopharmaceutical company's stock worth $72,000 after buying an additional 4,979 shares during the last quarter.  CWM LLC lifted its stake in  Esperion Therapeutics by 46.5% during the third quarter. CWM LLC now owns 19,674 shares of the biopharmaceutical company's stock worth $52,000 after purchasing an additional 6,249 shares during the last quarter.  DHJJ Financial Advisors Ltd. lifted its stake in  Esperion Therapeutics by 209.2% during the third quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 6,380 shares during the last quarter.  Wealth Enhancement Advisory Services LLC boosted its holdings in  Esperion Therapeutics by 54.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 23,916 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 8,394 shares during the period.  Finally, North Star Investment Management Corp. increased its stake in  Esperion Therapeutics by 40.0% during the third quarter. North Star Investment Management Corp. now owns 35,000 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own  47.39% of the company's stock. </p><h2>About Esperion Therapeutics</h2> (Get Free Report)<p>Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company's research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.  </p><p>The company's lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Esperion Therapeutics</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>[URGENT!] SpaceX Going Public! – Pre-IPO Action</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>Shots officially fired…</li><li>A month before the crash</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVNQUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVNQUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Esperion Therapeutics Right Now?</h2><p>Before you consider Esperion Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.</p><p>While Esperion Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ESPR

<p>Esperion Therapeutics, Inc. (NASDAQ:ESPR) has received an average "Moderate Buy" rating from eight research firms. Analysts have set an average 1-year price target of $7.20. The stock opened at $4.04, with a 12-month range of $0.69 to $4.13. Recent insider trading includes CFO Benjamin Halladay selling shares. Institutional investors hold 47.39% of the stock. Esperion focuses on LDL-C-lowering therapies, with lead product NEXLETOL approved in the U.S.</p>

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages